8-K

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) February 14, 2003

Varian Medical Systems, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware	1-7598	94-2359345
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
3100 Hansen Way, Palo Alto, CA		94304-1030
(Address of Principal Executive Offices)		(Zip Code)
Registrant’s telephone number, including area code		(650) 493-4000

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

TABLE OF CONTENTS

	Item 5. Other Events
	Item 7. Financial Statements and Exhibits
SIGNATURES
EXHIBIT INDEX
Exhibit 99.1
Exhibit 99.2

Item 5. Other Events.

     On February 14, 2003, Varian Medical Systems, Inc. (the “Company”) issued press releases announcing (i) the election of Dr. Allen S. Lichter, M.D. and Ruediger Naumann-Etienne, Ph.D. to its Board of Directors and (ii) the authorization by its Board of Directors of the repurchase by the Company of up to two million shares of its stock through the end of February 2004.

     Copies of the press releases are attached as exhibits hereto and are incorporated by reference herein.

Item 7. Financial Statements and Exhibits.

     (c)  Exhibits.

99.1	Press Release dated February 14, 2003 regarding the election of new directors
99.2	Press Release dated February 14, 2003 regarding repurchase of shares

2

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Varian Medical Systems, Inc.
	By: /s/ Elisha W. Finney Name: Elisha W. Finney Title: Vice President, Finance and Chief Financial Officer
Dated: February 14, 2003

3

EXHIBIT INDEX

Number	Exhibit
99.1	Press Release dated February 14, 2003 regarding the election of new directors
99.2	Press Release dated February 14, 2003 regarding repurchase of shares

EX-99.1

                                                                    EXHIBIT 99.1

                                                        FOR INFORMATION CONTACT:
                                                    Spencer Sias, (650) 424-5782

DR. ALLEN S. LICHTER AND RUEDIGER NAUMANN-ETIENNE
ELECTED TO VARIAN MEDICAL SYSTEMS' BOARD OF DIRECTORS

PALO ALTO, CALIF., FEBRUARY 14, 2003 - Varian Medical Systems, Inc. (NYSE:VAR)
today announced that Dr. Allen S. Lichter, M.D., and Ruediger Naumann-Etienne,
Ph.D., have been elected to its board of directors. The two new board members
are replacing Richard W. Vieser and Burton Richter, Ph.D., who have retired from
the seven-member body. Richard M. Levy, Ph.D., president and CEO of Varian
Medical Systems, has replaced Vieser as chairman of the board following his
election to that position in December. Board member Dr. David Martin, M.D., has
been re-elected to serve an additional three-year term.

         "We have made two excellent additions to our board to replace two board
members who have been of superb service to Varian over the years," said Levy.
"Allen Lichter brings deep knowledge of oncology as well as the economic,
social, and educational issues influencing the U.S. healthcare system. Ruediger
Naumann-Etienne combines expertise in finance with a wealth of experience in the
management and stewardship of medical technology enterprises. Their leadership
will be of great value as we continue to develop the Varian Medical Systems
business."

DR. ALLEN LICHTER

         Dr. Lichter is Dean of the University of Michigan Medical School and
Newman Family Professor of Radiation Oncology. He sits on the Board of Directors
of the Accreditation Council for Graduate Medical Education (ACGME). He received
his B.S. from the University of Michigan in 1968 and his M.D. from the
University of Michigan Medical School in 1972. He is a past president of the
American Society of Clinical Oncology and he has served on the Board of
Directors of the American Society of Therapeutic Radiologists and Oncology. He
was also Director of the Radiation Therapy Section of the National Cancer
Institute's Radiation Oncology Branch.

         At the University of Michigan Comprehensive Cancer Center, Dr. Lichter
served as Director of the Breast Oncology Program where he conducted
internationally recognized research that led to new treatment standards
emphasizing breast preservation by combining radiation therapy with a
lumpectomy.


                                     -more-

DR. ALLEN S. LICHTER AND RUEDIGER NAUMANN-ETIENNE
ELECTED TO VARIAN MEDICAL SYSTEMS' BOARD OF DIRECTORS

RUEDIGER NAUMANN-ETIENNE

         Naumann-Etienne is the owner and Managing Director of Intertec Group,
an investment company specializing in medical technology. He holds a Ph.D. in
International Finance from the University of Michigan, a Master's Degree in
Industrial Management from the Georgia Institute of Technology, and he completed
undergraduate work in Business Administration at the Technical University Berlin
in Germany.

         Naumann-Etienne currently is Chairman of the Board and CEO of Quinton
Cardiology Systems (NASDAQ:QUIN) in Bothell, WA. He also is a director for
Bio-Rad Laboratories (ASE:BIO) in Hercules, CA, and The Exploratorium science
museum in San Francisco.

         He served as CEO and Chairman of the Board of OEC Medical Systems in
Salt Lake City until General Electric acquired it in November of 1999. Earlier,
he served as President, Chief Operating Officer, and Chief Financial Officer of
Diasonics in Milpitas. He also worked for Hambrecht and Quist in San Francisco
and he held various management positions at Texas Instruments in Dallas
including Group Controller.

                                      # # #

VARIAN MEDICAL SYSTEMS, INC., (NYSE:VAR) OF PALO ALTO, CALIFORNIA IS THE WORLD'S
LEADING MANUFACTURER OF INTEGRATED CANCER THERAPY SYSTEMS, WHICH ARE TREATING
THOUSANDS OF PATIENTS PER DAY. THE COMPANY IS ALSO A PREMIER SUPPLIER OF X-RAY
TUBES AND FLAT-PANEL DIGITAL SUBSYSTEMS FOR IMAGING IN MEDICAL, SCIENTIFIC, AND
INDUSTRIAL APPLICATIONS. VARIAN MEDICAL SYSTEMS EMPLOYS APPROXIMATELY 2,750
PEOPLE WHO ARE LOCATED AT MANUFACTURING SITES IN NORTH AMERICA AND EUROPE AND IN
ITS 50 SALES AND SUPPORT OFFICES AROUND THE WORLD. IN ITS MOST RECENT FISCAL
YEAR ENDED SEPTEMBER 27, 2002, VARIAN MEDICAL SYSTEMS REPORTED SALES OF $873
MILLION. ADDITIONAL INFORMATION IS AVAILABLE ON THE COMPANY'S INVESTOR RELATIONS
WEB SITE AT WWW.VARIAN.COM

FORWARD LOOKING STATEMENTS

Except for historical information, this news release contains "forward-looking"
statements within the meaning of the Private Securities Litigation Reform Act of
1995. For this purpose, statements concerning the anticipated anti-dilutive
effect of stock repurchases and any statements using the terms "should,"
"expect," or similar statements are forward-looking statements that involve
risks and uncertainties that could cause our actual results to differ materially
from those projected. Such risks and uncertainties include, without limitation,
the risks listed from time to time in our filings with the Securities and
Exchange Commission. We assume no obligation to, and you should not expect us
to, update or revise the forward-looking statements in this release.

EX-99.2

                                                                    EXHIBIT 99.2

                                                        FOR INFORMATION CONTACT:
                                                   Spencer Sias - (650) 424-5782

VARIAN MEDICAL SYSTEMS' BOARD OF DIRECTORS AUTHORIZES REPURCHASE OF ANOTHER
TWO MILLION SHARES OF STOCK

PALO ALTO, CALIF., FEBRUARY 14, 2003 - Varian Medical Systems, Inc. (NYSE:VAR)
today announced that its Board of Directors has authorized the Company to
repurchase up to two million shares through the end of February 2004. The new
authorization is effective immediately and follows the completion of an earlier
repurchase authorization.

         "We're generating operating cash flow of about $40 million per quarter
and we expect that the continuation of our stock repurchase program will be
accretive to earnings," said Richard M. Levy, chairman, president and CEO of
Varian Medical Systems. "These stock repurchases should enhance shareholder
value by helping to offset dilution from employee stock option exercises and our
employee stock purchase program."

         Under the earlier repurchase authorization that became effective in
August, 2001, Varian Medical Systems spent $83.7 million to repurchase two
million shares of stock at an average price of $41.86 per share. As of the end
of the first fiscal quarter ended December 27, 2002, the company reported $321
million in cash and marketable securities.

         The stock repurchases will be made from time to time through brokers
and dealers on the New York Stock Exchange on in privately negotiated
transactions with nonaffiliated stockholders. Shares will be retired and
cancelled upon repurchase.

                                      # # #

VARIAN MEDICAL SYSTEMS, INC., (NYSE:VAR) OF PALO ALTO, CALIFORNIA IS THE WORLD'S
LEADING MANUFACTURER OF INTEGRATED CANCER THERAPY SYSTEMS, WHICH ARE TREATING
THOUSANDS OF PATIENTS PER DAY. THE COMPANY IS ALSO A PREMIER SUPPLIER OF X-RAY
TUBES AND FLAT-PANEL DIGITAL SUBSYSTEMS FOR IMAGING IN MEDICAL, SCIENTIFIC, AND
INDUSTRIAL APPLICATIONS. VARIAN MEDICAL SYSTEMS EMPLOYS APPROXIMATELY 2,750
PEOPLE WHO ARE LOCATED AT MANUFACTURING SITES IN NORTH AMERICA AND EUROPE AND IN
ITS 50 SALES AND SUPPORT OFFICES AROUND THE WORLD. IN ITS MOST RECENT FISCAL
YEAR ENDED SEPTEMBER 27, 2002, VARIAN MEDICAL SYSTEMS REPORTED SALES OF $873
MILLION. ADDITIONAL INFORMATION IS AVAILABLE ON THE COMPANY'S INVESTOR RELATIONS
WEB SITE AT WWW.VARIAN.COM

         FORWARD LOOKING STATEMENTS

Except for historical information, this news release contains "forward-looking"
statements within the meaning of the Private Securities Litigation Reform Act of
1995. For this purpose, statements concerning the anticipated anti-dilutive
effect of stock repurchases and any statements using the terms "should,"
"expect," or similar statements are forward-looking statements that involve
risks and uncertainties that could cause our actual results to differ materially
from those projected. Such risks and uncertainties include, without limitation,
the risks listed from time to time in our filings with the Securities and
Exchange Commission. We assume no obligation to, and you should not expect us
to, update or revise the forward-looking statements in this release.